Posts

Showing posts with the label reimbursement
Show all
Image

EU Joint Clinical Assessment after the first reports: How should companies interpret the findings?

Image

Anti-Amyloid Drugs in Alzheimer’s: Breakthrough, Dead End, or Reimbursement Reality Check?

Image

China’s NRDL: The World’s Largest Market Access Event Is Underway

Image

GLP-1s and the Rise of Consumer-Led Pharma: What the Obesity Market Signals for the Future of Access

Image

Access To The New Alzheimer's Drugs: Why HTA Bodies Are Saying No

Image

Changes in Market Access in Europe and Implications for Clinical Development Planning: Joint Clinical Assessments